viewParadigm Biopharmaceuticals Ltd

Paradigm Biopharmaceuticals receives positive results for Ross River clinical trial

The trial was treating patients with joint pain or joint stiffness.

clinical trial folder
The primary endpoint of safety was met and reduced disease symptoms were evident

Paradigm Biopharmaceuticals Ltd (ASX:PAR) has met its primary endpoint of safety in its pilot phase IIa clinical trial for chronic Ross River virus (RRV) induced arthralgia.

18 patients were dosed, 11 with injectable pentosan polysulfate sodium (iPPS) and 7 with placebos.

Importantly, the primary endpoint of safety was met and encouragingly results demonstrated iPPS reduced RRV disease symptoms compared to the placebo.

For example, at the 3-month follow-up, 72.7% or 8 of the 11 subjects in the iPPS group showed near remission of symptoms based on Rapid-3 disease assessment in contrast to 14.3% or 1 of the 7 in the placebo group.

RAPID-3 scores are correlated with clinical disease activity and enable the quantitative monitoring and documenting of improvement or worsening over time.

A reduction in Rapid 3 signifies improvement in clinical disease activity.

Successful results to progress commercial discussions

Paradigm’s CEO Paul Rennie said: “We are very pleased to see that this small pilot RRV study has yielded very promising safety data and key efficacy outcomes in the reduction of disease symptoms in this debilitating chronic phase of the disease.

“The human data on the effects of iPPS in RRV induced arthralgia together with our preclinical work on CHIK-V will progress our commercial discussions with US Department of Defense.”

READ: Paradigm Biopharmaceuticals receives more positive real-world patient data

Recently, Paradigm also received real-world data from 22 more patients with knee osteoarthritis (OA) treated with iPPS.

This increased the total real-world patients treated with iPPS to 205 with a recorded 51.3% reduction in pain.

The 51.3% average reduction in pain score across 205 subjects with knee OA, continues to demonstrate iPPS’s superiority over the 15% pain reduction scores reported for opioid treatments for chronic pain in OA of the knee and hip.

Paradigm is aiming to achieve Fast-Track designation and begin a phase 3 trial in the US in CY2019, both these initiatives are expected to attract significant big pharma interest.

Quick facts: Paradigm Biopharmaceuticals Ltd

Price: 2.71 AUD

Market: ASX
Market Cap: $618.08 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Paradigm Biopharmaceuticals Ltd named herein, including the promotion by the Company of Paradigm Biopharmaceuticals Ltd in any Content on the...


Paradigm's drug developments sees growing market opportunities

Paul Rennie, chief executive for Paradigm Biopharmaceuticals, speaks with Proactive Investors.

on 18/8/17

2 min read